Physician profile
Patrick Thomas Griffin
NPI 1386963015
$1,057.76
in general payments reported to CMS, 2019-2025
23 companies · $20.96 in 2025
The $20.96 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569 · 2021: $58.02 · 2022: $126 · 2023: $112 · 2024: $172 · 2025: $20.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $304.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $199.11 | 2019-2024 | Reblozyl |
| Pfizer INC. | $145.80 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $95.27 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $82.05 | 2019-2025 | Opdualag |
| Genentech USA, INC. | $80.48 | 2019-2024 | Tecentriq, Tecentriq Hybreza, Alecensa |
| Janssen Biotech, INC. | $61.80 | 2019 | |
| Abbvie INC. | $50.50 | 2019-2023 | |
| Amgen INC. | $39.47 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $33.66 | 2019 | |
| Array Biopharma INC | $27.32 | 2024 | Mektovi, Xalkori, Lorbrena |
| Pharmacyclics LLC, An Abbvie Company | $27.08 | 2019 | |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Exelixis INC. | $22.42 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $19.93 | 2019 | |
| Tempus Ai, INC | $19.80 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $19.27 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.00 | 2019 | |
| Pharmaessentia USA Corporation | $17.80 | 2022 | |
| Merck Sharp & Dohme LLC | $17.56 | 2019 | |
| Glaxosmithkline, LLC. | $15.83 | 2023 | |
| Taiho Oncology, INC. | $14.84 | 2019 | |
| Seagen INC. | $13.92 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.